**Summary**
OptiBiotix Health plc, a life sciences company specializing in products that reduce hunger, enhance the gut microbiome, and provide healthy sugar substitutes, has announced significant commercial progress for 2026. The company has secured four large orders totaling 24 metric tonnes of its SlimBiome product from Meelung Trading, Taiwan, a major nutritional supplement distributor. These orders, valued at over £800K, will be delivered throughout 2026 and reflect growing confidence in SlimBiome as a natural alternative to GLP-1 anti-obesity drugs. The early orders from Meelung and three other partners position OptiBiotix for a strong FY2026, enabling better cost management and margin improvement.
The company highlights the rapid growth of the GLP-1 alternative market, projected to reach $4.8 billion by 2033, and emphasizes SlimBiome’s competitive edge with its clinical studies, international awards, and health claims. CEO Stephen OHara expressed optimism about the record start to 2026 and the company’s strengthened position, while also noting continued growth in 2025 and progress in scaling up second-generation products. OptiBiotix remains focused on leveraging its microbiome-based technologies across health and skincare markets, with a diverse portfolio of products and subsidiaries.